Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AIM ImmunoTech Inc. Director's Dealing 2012

Jun 7, 2012

35334_dirs_2012-06-07_dd609b0f-d08a-4330-b908-22bfaa657f1c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2012-06-05

Reporting Person: PIANI RICHARD (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2012-06-05 Options to buy Common Stock $0.29 J 100000 Acquired 2022-06-05 Common Stock (100000) Direct

Footnotes

F1: Board of Directors granted options to purchase shares of HEB common stock.